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Víctor Campos Arillo6, Nélida Susana Garretto7, Tomoko Arakaki7, Marcos Serrano Dueñas8, Mario Álvarez9, Ivonne Pedroso Ibáñez9,
Ana Carvajal1 and Pablo Martínez-Martín3
Understanding how a person lives with a chronic illness, such as Parkinson’s disease (PD), is necessary to provide individualized care
and professionals role in person-centered care at clinical and community levels is paramount. The present study was aimed to
analyze the psychometric properties of the Living with Chronic Illness-PD Scale (EC-PC) in a wide Spanish-speaking population with
PD. International cross-sectional study with retest was carried out with 324 patients from four Latin American countries and Spain.
Feasibility, acceptability, scaling assumptions, reliability, precision, and construct validity were tested. The study included 324
patients, with age (mean± s.d.) 66.67 ± 10.68 years. None of the EC-PC items had missing values and all acceptability parameters
fulﬁlled the standard criteria. Around two-third of the items (61.54%) met scaling assumptions standards. Concerning internal
consistency, Cronbach’s alpha values were 0.68–0.88; item-total correlation was 40.30, except for two items; item homogeneity
index was 40.30, and inter-item correlation values 0.14–0.76. Intraclass correlation coefﬁcient for EC-PC stability was 0.76 and
standard error of measurement (s.e.m.) for precision was 8.60 (for a EC-PC s.d. = 18.57). EC-PC presented strong correlation with
social support (rS = 0.61) and moderate correlation with life satisfaction (rS = 0.46). Weak and negligible correlations were found with
the other scales. Internal validity correlations ranged from 0.46 to 0.78. EC-PC total scores were signiﬁcantly different for each
severity level based on Hoehn and Yahr and Clinical Impression of Severity Index, but not for Patient Global Impression of Severity.
The EC-PC has satisfactory acceptability, reliability, precision, and validity to evaluate living with PD.
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INTRODUCTION
Demographic changes happening in the twentieth century in the
Western world such as ageing and increase in life expectancy have
produced a signiﬁcant growth in chronic illnesses in the
contemporary society. In particular, chronic diseases have become
a leading health-related issue.1
Among chronic diseases, neurodegenerative and progressive
disorders such as Parkinson’s Disease (PD) stand out. PD is the
second most common neurodegenerative disease, after
Alzheimer’ disease, affecting 1% of all people over 60 years of
age in industrialized countries.2 PD prevalence is increasing and it
is expected that the number of PD patients will double by 2030.3
PD is a complex and disabling disorder manifested through a
combination of characteristic motor signs, such as bradykinesia,
rigidity, resting tremor, and postural instability and non-motor
symptoms such as, for example, psychiatric disorders, autonomic
disturbances, pain, and fatigue.4 Throughout the PD course,
patients experience a progressive intensiﬁcation of symptoms and
increasing limitations to the performance of daily activities.
Living with a chronic illness, such as PD, is a complex, dynamic,
cyclic, and multidimensional process that involves such compo-
nents as Acceptance, Coping, Self-management, Integration, and
Adjustment.5 Several studies show that living with a chronic
illness, as PD does not only affect the patients’ physical state but
also other aspects in their lives, such as the emotional and social
ones.5–7 In this context, healthcare professionals need to adopt an
integral approach so that all aspects of the person, understood as
a bio-psychosocial and spiritual being, are addressed.6–8 In
particular, clinical specialists have an essential role in facilitating
the patient’s living with PD process and, consequently, improving
his/her quality of life and well-being.7,8 It is, therefore, important
to have available tools for assessing living with PD from the
patient’s perspective, in combination with clinical tools that focus
on speciﬁc signs and disabilities of PD. Nowadays, despite the
great number of existing measures, there are no tools to evaluate
the process of living with a chronic illness, such as PD. In
particular, the existing tools evaluate the process in a fragmented
way. For example, the Scales for Outcomes in Parkinson’s Disease-
Psychosocial (SCOPA-PS)9 only evaluates the psychosocial adjust-
ment to PD without bearing in mind other components of the
daily living with the disease such as Acceptance or Self-manage-
ment, for example. In this way, the Living with Chronic Illness-PD
Scale (EC-PC, from Spanish ‘Escala deConviviencia con un
ProcesoCrónico’) is the only available tool in clinical practice and
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research to evaluate how the patient is living with PD in a
comprehensive manner, focusing on the person and not on the
disease. The EC-PC is an innovative self-reported scale, recently
developed,10 waiting validation studies for testing its psycho-
metric properties. To this purpose, an international collaborative
study was carried out in Argentina, Ecuador, Cuba, Mexico, and
Spain. The objective of this study was to analyze the psychometric
properties of the EC-PC in a wide, multinational Spanish-speaking
population.
RESULTS
Three-hundred twenty-four patients diagnosed with PD, 52.78%
men, mean (± s.d.) age 66.67 ±10.68 (range: 36–94) years were
included. In this sample, age at the onset of PD was 56.90 ± 10.92
(range: 24–84) and disease duration 9.76 ± 5.71 (1–28) years.
Patients were receiving treatment for PD during 8.82 ± 5.65 (range:
0–28) years and their distribution according the Hoehn and Yahr
(HY) stages was: 8.64% in stage 1; 55.25%, stage 2; 30.56%, stage 3;
4.01, stage 4; and 1.54% in stage 5. Two-third (66.36%) were
married, 42.90% were retired, and 63.58% had primary or
secondary education levels. Table 1 shows the descriptive
statistics for disease-related variables and assessments in the
study and the EC-PC. Patient-based Global Impression of Severity
Scale (PGIS) median (interquartile range) was 3 (2–3).
Feasibility and acceptability
None of the items had missing values. All acceptability parameters
fulﬁlled the standard criteria. Speciﬁcally, ﬂoor or ceiling effects
were o15% (both, 0.31 for the total score) and skewness values
were between − 1 and +1 (Table 2).
Scaling assumptions. Mean and s.d. values were roughly equiva-
lent, ranging from 1.74 to 3.01 (means) and 1.18 to 1.56 (s.d.).
Multitrait-scaling analysis showed that 61.54% of the items had a
correct location in their respective domains, whereas the rest of
the items (38.46%) performed as “possible errors” in their location.
Cronbach’s alpha was 40.70 for all domains, except for
dimension 3-Self-management (alpha = 0.68). Two items (12 and
13; 7.69%) did not reach the preset 0.30 threshold value for item-
total correlation. Item homogeneity index values were 40.30 for
all domains and inter-item correlation coefﬁcient values ranged
from 0.14 to 0.76 (Table 2), with only four items (15%, from the
domains 2, 3, and 5) under the standard value 0.20.
Test–retest reliability was determined in 55 patients. The ICC for
the total scale score was 0.76 and for the dimensions was ⩾ 0.60,
except for the domain 3-Self-management (Table 2). For individual
items, weighted kappa ranged from 0.22 (item 13) to 0.80 (item 2).
SEM for EC-PC total score was 8.60 (o½ s.d.: 8.78) and for the
dimensions ranged from 1.51 to 2.98, where two of them were
o½ s.d. (domain 1-Acceptance and 5-Adjustment; Table 2).
Convergent validity results are shown in Table 3. Correlation
coefﬁcient between EC-PC total scores and Duke-UNC Functional
Social Support Questionnaire (DUFSS) was 0.61 (strong), whereas
correlation between the EC-PC and Satisfaction with Life as a
whole was 0.46 (moderate). The EC-PD domain 1-Acceptance
showed also moderate correlations with some components of the
Satisfaction with Life Scale. EC-PC presented weak correlations
with the SCOPA-PS total scale (Table 3). Weak or negligible
correlations were found between EC-PC and the clinician-based
PD assessments.
Internal validity analysis showed that correlation values
between the EC-PC domains ranged from 0.46 to 0.78, except
for dimension 1-Acceptance that showed poor correlations with
the other dimensions (Table 3).
EC-PC known-groups validity analysis showed that total scores
were signiﬁcantly different for each category of severity (mild,
moderate, and severe) based on the HY and CISI-PD, but not for
the PGIS (Table 4).
DISCUSSION
For this ﬁrst validation study of the EC-PC, carried out in patients
with PD, most of the tested psychometric properties resulted in
satisfactory values. The patients included in the study (n= 324)
were considered representative of the PD population attending
specialized hospital departments or movement disorder units,
with over 85% of patients in mild or moderate levels of severity
(Table 1). On the other hand, the participation of Spanish-speaking
patients from several countries supports the consistency of the
results at least for this cultural and linguistic setting.
Concerning the speciﬁc validation aspects, EC-PC feasibility and
acceptability were satisfactory. Quality of data was excellent, with
100% of cases fully computable, probably due to the close
supervision of the participant researchers after completion of the
scale by patients. Floor and ceiling effects and the skewness
Table 1. Summary of the measures applied in the study
Mean s.d. Median Observed range Theoretical range
SCOPA-Motor 22.34 11.26 22 1–68 0–75
CISI-PD 7.61 4.00 7 0–24 0–24
Non-Motor Symptoms Scale 60.36 46.76 51 0–243 0–360
SCOPA- Psychosocial 9.71 6.49 8.5 0–29 0–33
DUFSS 27.66 10.00 28 1–44 1–55
Satisfaction with Life (whole) 6.75 1.96 7 0–10 0–10
EC-PC
Domain 1. Acceptance 7.90 4.68 8 0–16 0–16
Domain 2. Coping 17.27 6.79 17 0–28 0–28
Domain 3. Self-management 10.35 3.77 10 0–16 0–16
Domain 4. Integration 13.52 4.70 14 0–20 0–20
Domain 5. Adjustment 13.41 6.02 13 0–24 0–24
EC-PC total score 62.45 18.57 62 22–104 0–104
Abbreviations: CISI-PD, Clinical Impression of Severity Index-PD; DUFSS, Duke-UNC Functional Social Support Questionnaire; EC-PC, Living with Chronic illness-
PD Scale; PGIS, Patient-based Global Impression of Severity Scale; SCOPA-Motor, Scales for Outcomes in Parkinson’s Disease-Motor; SCOPA-Psychosocial, Scales
for Outcomes in Parkinson’s Disease-Psychosocial.
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values were into the stipulated range of satisfactory values
(Table 2). These ﬁndings showed that EC-PC covers the full
spectrum of intensity of the construct, with an adequate
distribution of the scores suitable to PD population.
Scaling assumptions were deemed acceptable as a whole. The
range of means and s.d. distribution were roughly equivalent and
61.54% of the items had a correct location in their corresponding
domains. The rest of the items performed in this analysis as
“possible errors” in their location, although qualitative data
emerged from previous studies in PD6,7 support the adequacy of
their location. Moreover, other tools for assessment of living with
chronic illness components such as Coping and Self-management
also include items with a similar content to those identiﬁed
as possible errors in EC-PC (e.g., Brief-Cope, Diabetes Self-
Management Questionnaire).
EC-PC Cronbach’s alpha reﬂects satisfactory intercorrelations
between items of the domains composing the EC-PC, except for
domain 3-Self-management that was just under the limit of the
acceptable 0.70 threshold value (Table 2). However, qualitative
studies5–7 showed the suitability of the items contained into
Self-management domain and, therefore, this result could be
considered acceptable. Item-total correlation coefﬁcients were
over the minimal standard threshold, except for the items 12 and
13 that showed a low item-total correlation (Table 2). These
statistical results differ from previous qualitative studies,5–7 which
conﬁrmed that both items are intrinsic characteristics of their
respective dimensions. Concerning the inter-item correlation,
85% of the items showed adequate coefﬁcient values according
the standards,11,12 a fact reﬂected in satisfactory item
homogeneity indexes for all domains. To summarize, most of
the EC-PC internal consistency parameters were satisfactory as
a whole.
Test–retest reliability was satisfactory for the total scale and for
the dimensions, except for domain 3-Self-management that
Table 2. Feasibility/acceptability, reliability, and precision of the EC-PC
EC-PC
Domain 1. Acceptance Domain 2. Coping Domain 3. Self-management Domain. 4 Integration Domain 5. Adjustment
Data quality (%) 100 100 100 100 100
Floor effect (%) 3.70 0.93 0.31 0.62 0.93
Ceiling effect (%) 7.41 4.63 12.96 8.02 7.41
Skewness 0.16 − 0.29 − 0.21 − 0.82 0.05
Cronbach’s alpha 0.88 0.86 0.68 0.82 0.79
Item-total correlation 0.64–0.80 0.25–0.80 0.21–0.64 0.42–0.77 0.38–0.76
Inter-item correlation 0.55–0.76 0.14–0.73 0.19–0.69 0.25–0.63 0.16–0.70
Item homogeneity 0.65 0.48 0.42 0.47 0.40
Reproducibilitya 0.85 0.61 0.57 0.60 0.81
Precision (s.e.m.) (1/2 s.d.) 1.51 (1.96) 2.83 (2.27) 1.70 (1.30) 2.31 (1.83) 2.98 (3.42)
Abbreviation: EC-PC, Living with Chronic Illness Scale.
aIntraclass correlation coefﬁcient.














Hoehn and Yahr staging − 0.17 − 0.05 − 0.02 − 0.13 − 0.02 − 0.09
CISI-PD − 0.25 − 0.07 − 0.03 − 0.14 − 0.15 − 0.16
SCOPA-Motor − 0.27 − 0.01 0.07 − 0.03 − 0.14 − 0.08
Non-Motor Symptoms Scale − 0.36 − 0.23 − 0.18 − 0.24 − 0.19 − 0.32
SCOPA-Psychosocial − 0.40 − 0.09 − 0.08 − 0.23 − 0.24 − 0.25
DUFSS 0.12 0.61 0.57 0.57 0.36 0.61
Satisfaction—With Life as a whole 0.43 0.29 0.28 0.33 0.48 0.46
With physical health 0.32 0.15 0.15 0.26 0.27 0.28
With psychological well-being 0.40 0.22 0.21 0.26 0.34 0.35
With social relations 0.41 0.24 0.23 0.30 0.34 0.38
With leisure 0.40 0.29 0.26 0.36 0.41 0.43
With ﬁnancial situation 0.38 0.05 0.05 0.10 0.24 0.18
Internal validity
Domain 2. Coping − 0.00 — — — — —
Domain 3. Self-management 0.01 0.78 — — — —
Domain 4. Integration − 0.04 0.71 0.73 — — —
Domain 5. Adjustment 0.23 0.54 0.47 0.46 — —
Abbreviations: CISI-PD, Clinical Impression of Severity Index-PD; DUFSS, Duke-UNC Functional Social Support Questionnaire; EC-PC, Living with Chronic illness-
PD Scale; SCOPA-Motor, The Scales for Outcomes in Parkinson’s Disease-Motor; SCOPA-Psychosocial, Scales for Outcomes in Parkinson’s Disease-Psychosocial.
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reached an ICC marginally o0.60 (Table 2). The circumstances for
data collection in the ﬁrst application and in the retest were
different (see Materials and Methods—Test–retest assessment).
This methodological difference could have introduced additional
variability in the scores stability and, besides other factors not
controlled in the study, could have inﬂuenced the responses.13
The EC-PC total score precision was satisfactory (Table 2).
Nonetheless, the results for the dimensions 2, 3, and 4 were
minimally out of the proposed standard, suggesting that those
domains may be somewhat less sensitive (precise) than expected.
SEM is a fairly stable parameter among different samples,14 but
future studies will have to conﬁrm the precision weakness of these
three EC-PC dimensions if the reliability coefﬁcient (derived from
the test–retest) is obtained following a different approach than in
the present study.
The correlations of EC-PC with DUFSS and Satisfaction with Life
as a whole resulted, as it was hypothesized on the basis of the
conceptual relationships between their respective constructs,
strong, and moderate, respectively. These ﬁndings are consistent
with the previous studies6,7 showing the relationships between
social support and satisfaction with the process of living with PD.
However, an unexpected weak relationship between EC-PC and
SCOPA-PS was found, suggesting that living with PD was quite
independent of the psychosocial adjustment to the disease. From
a conceptual point of view, this ﬁnding has not an easy
explanation and, in fact, an at least moderate association was
expected. Some potential reasons for such discrepancy could be
(1) both concepts really are loosely related; (2) the EC-PC or the
SCOPA-PS does not assess what it intends to measure; or (3) the
population participating in the present study has peculiarities in
these aspects. None of these speculative explanations, however,
seems to be convincing. Again, future studies should verify the
ﬁnding and clarify these points.
On the other hand, the association between EC-PC and the
clinician-based assessments was weak or negligible (Table 3),
although a moderate or weak relationship was expected. In this
context, the different sources of information (patient versus
clinician) and the difference between the constructs evaluated by
both types of assessments (e.g., physical signs versus disease
acceptance) can explain, at least in part, their weak correlation. In
addition, intrinsic individual (e.g., personality and beliefs) and
environmental (e.g., social networks and social support) char-
acteristics broadly differ among subjects, circumstances able to
inﬂuence with a wide degree of variability the EC-PC, but not the
PD manifestations.
Internal validity for EC-PC dimensions was satisfactory, except
for domain 1-Acceptance (Table 3). This result could be explained
with previous qualitative studies,5–7 showing that Acceptance of
disease is always the ﬁrst process necessary to achieve a positive
living with the condition, because only when the person has
accepted his/her illness, can move on to other processes. Thereby,
according to the quantitative data emerged in this study and
based on the previous qualitative studies, Acceptance is
considered an internal, illness-independent, process through
which the patient recognizes and assumes the reality.
EC-PC demonstrated satisfactory known-groups validity, yield-
ing signiﬁcantly different scores between patients with different
PD severity levels based on HY and CISI-PD (Table 4). No
signiﬁcant differences were found in regard to the PGIS severity
levels due to the closeness of EC-PC scores for mild and moderate
levels, although both were higher (better) than for the severe
group, as observed with HY and CISI-PD. These results are
congruent with the previous studies carried out in PD,6,7 showing
that patients in early stages of the disease present a better degree
of living with PD (positive living) than patients in more advanced
stages (negative living).
Main limitations of the study are: (1) the study was not
performed on a population basis but in a specialized setting; (2)
there are not data on patients with cognitive deterioration,
although eight patients (2.5%) meeting all criteria for inclusion
were qualiﬁed as with cognitive impairment according to the
CISI-PD item 4, which was the last assessment performed by the
neurologist in the ﬁeld work; and (3) modiﬁcation of the
procedure between test (in ofﬁce) and retest (at home), a
circumstantial change probably adding spurious variability.
In conclusion, this ﬁrst validation study of the EC-PC showed
that the scale feasibility and acceptability are satisfactory, whereas
presents some weaknesses in reliability and precision parameters,
although they do not affect the scale total score. As a whole, the
analyzed modalities of validity were deemed satisfactory. Addi-
tional adaptation and validation studies are needed, in other
settings and populations, to identify the shared components of




This was an open, international, cross-sectional (one point-in-time
evaluation, with retest) study.
Patients
The sample was composed of consecutive PD outpatients from participant
centers. Patients were assessed in the period from January to June 2015.
Inclusion criteria were: (1) patients with diagnosis of PD by a neurologist
according to the international recognized diagnostic criteria;4 (2) native
Spanish-speaking patients from ﬁve countries (Argentina, Cuba, Ecuador,
Mexico, and Spain); (3) able to read and understand properly ques-
tionnaires; and (4) able to provide informed consent. Exclusion criteria
were: (1) parkinsonism other than PD; (2) concomitant severe systemic
condition; (3) cognitive deterioration previously and formally diagnosed by
the neurologist; (4) acute disorder or injury, pharmacological effect (e.g.,
dopamine antagonists), or sensorial deﬁcit (e.g., blindness) potentially
distorting the assessment; and (5) refusal to participate or patients who did
not meet all inclusion criteria.
Table 4. Known-groups validity
Categories EC-PC total P valuea
HY-based severity levelsb








Mild 63.28± 19.33 NS
Moderate 64.94± 17.15
Severe 47.03±13.37
Abbreviations: CISI-PD, Clinical Impression of Severity Index for Parkinson’s
Disease; EC-PC, Living with Chronic illness-PD Scale; HY, Hoehn and Yahr
staging; NS, nonsigniﬁcant; PGIS, Patient-Based Global Impression of
Severity Scale.
aKruskal–Wallis test.
bHY-based severity levels: mild, stages 1 and 2; moderate, stage 3; severe,
stages 4 and 5.
cCISI-PD severity levels: mild 1–7 points; moderate 8–14 points; severe 15
or more points.
dPGIS-based severity levels: mild 0–2 points; moderate 3 points; severe 4 or
more points.
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Assessments
In addition to sociodemographic and PD historic data, the following
measures were used:
HY staging,15 a ﬁve-level classiﬁcation universally used to provide a
global estimate of PD progression.
Scales for Outcomes in Parkinson’s Disease-Motor (SCOPA-Motor).16,17
An assessment including 21 items in three sections: Examination, Activities
of daily living, and Motor complications. Each item scores from 0 (normal)
to 3 (severe) and the total scale score is 0–75.
The Clinical Impression of Severity Index-PD (CISI-PD)18,19 evaluates the
global impression of PD severity in four areas: Motor signs; Disability; Motor
complications; and Cognitive status. Items are rated from 0 (normal) to 6
(very severe) and the total score runs from 0 to 24.
Non-Motor Symptoms Scale. Assessment for the burden of non-motor
symptoms in PD.20,21 It includes 30 items in nine domains. Each item is
scored for frequency and severity, from 0 (no present) to 12 (maximum
frequency and severity). Total scores for the domains and the whole scale
can be obtained by the sum of the corresponding items scores.
The SCOPA-PS9,22 is an 11-item questionnaire assessing psychosocial
functioning during the preceding month. Items are scored from 0 (not at
all) to 3 (very much), with higher scores denoting greater difﬁculty. The
summary index is obtained by the sum of item scores transformed into
percentage values.
DUFSS23,24 is an 11-item scale for assessing diverse dimensions of social
support including conﬁdant, affective, and instrumental support. Scores
range from 11 (lowest level “much less than I would like”) to 55 (highest
level “as much as I like”).
Satisfaction with Life Scale. The version used in the present study is a
six-item scale to measure the degree of Satisfaction with Life as a whole
(item 1) and in regard to ﬁve areas: physical, psychological well-being,
social relations, leisure, and ﬁnancial situation.25 Each item scores from 0
(unsatisﬁed) to 10 (totally satisﬁed).
Patient-based Global Impression of Severity Scale. An adaptation of the
clinical global impression of severity 26 for patients self-application.27 It is
rated on a six-point Likert-type scale ranging 0 (not ill at all) to 5
(extremely ill).
The EC-PC is a self-reported scale to evaluate how the patient is living
with a chronic illness as PD.10 For the validation study, a 27-item version
was used. However, interim testing of the internal consistency showed
poor performance of one item and it was removed. Consequently, the ﬁnal
version of EC-PC is a 26-item scale with ﬁve domains: 1-Acceptance
(4 items); 2-Coping (7 items); 3-Self-management (4 items); 4-Integration
(5 items); and 5-Adjustment (6 items). Items are scored on a ﬁve-point
Likert scale ranging from 0 (never/nothing) to 4 (always/a lot), except for
domain 1-Acceptance that ranges upside down (4: never/nothing;
0: always/a lot). Total score ranges from 0 (negative living with PD) to
104 (positive living with PD).
Test–retest assessment
For test–retest analysis, the EC-PC was applied a second time to a
consecutive subset of stable patients as per the PGIS (test: in ofﬁce; retest:
at home, post mail). A minimum sample of 50 subjects and a time span of
7–10 days for the retest was planned.
Ethical aspects
The study was approved by the Ethics Committee of the University of
Navarre and all participating centers. Patients gave their signed consent to
participate after receiving the pertinent information.
Data analysis
Descriptive statistics (central tendency measures, proportions) were used
as needed. Main data were ordinal or did not ﬁt normal distribution;
therefore, non-parametric statistics were used. A minimal sample of 10
patients per EC-PC item and 60 per country (n=300) was proposed. The
following psychometric attributes were tested:
Feasibility and acceptability. Quality of data was considered satisfactory if
95% of the data were computable. The limit for missing data was o5%.11
Floor and ceiling effect were deemed acceptable if they were o15% 28
and the skewness was expected between − 1 and +1.29
Scaling assumptions were checked attending the range of means and s.
d. distribution (roughly equivalent).11,30 Also, multitrait-scaling analysis was
carried out to check out the appropriate location of items in their
correspondent dimensions.31
Internal consistency was tested by Cronbach’s alpha coefﬁcient (criterion
value 40.70),32 item-total correlation (corrected for overlap; criterion
value, rs⩾ 0.30),29,33 inter-item correlation (criterion value, r⩾ 0.20 and
⩽ 0.75),11,12 and item homogeneity (criterion value 40.30).34
Reproducibility (test–retest) was determined using weighted kappa
(with quadratic weights) for items (standard, 40.41 moderate)35 and
intraclass correlation coefﬁcient (one way, random effect; ICC) for domains
and total score. Values ⩾ 0.60 were considered acceptable.31,36
Precision for each EC-PC domain and total score was estimated by
means of the standard error of measurement (s.e.m. = s.d. ×√[1− rxx]),32
where rxx was the reliability coefﬁcient, ICC. A s.e.m. value o½ s.d. was
used as criterion of acceptable precision.37
Construct validity: For convergent validity, a moderate (rs⩾ 0.35–0.50)
or strong relationship (rs40.50)
38–40 was hypothesized between EC-PC and
DUFSS, SCOPA-PS, and Satisfaction Scale, and a weak/moderate associa-
tion between EC-PC and the clinical, rater-based PD assessments in the
study. Spearman rank correlation coefﬁcients were obtained to this
purpose. Internal validity, deﬁned as the intercorrelations between the EC-
PC dimensions (standard, rs = 0.30–0.70)
29,33 and known-groups validity for
disease stage (HY); disease severity levels (CISI-PD); and PGIS scores were
determined. Mann–Whitney and Kruskal–Wallis tests were used for groups
comparison.
Stata 13 (Stata Corp., College Station, TX, USA) was used for data
analysis.
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